CN112336663A - 一种中药漱口水 - Google Patents
一种中药漱口水 Download PDFInfo
- Publication number
- CN112336663A CN112336663A CN202011392554.2A CN202011392554A CN112336663A CN 112336663 A CN112336663 A CN 112336663A CN 202011392554 A CN202011392554 A CN 202011392554A CN 112336663 A CN112336663 A CN 112336663A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- mouthwash
- parts
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 239000002324 mouth wash Substances 0.000 title claims abstract description 65
- 229940051866 mouthwash Drugs 0.000 title claims abstract description 63
- 239000000284 extract Substances 0.000 claims abstract description 25
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000003443 antiviral agent Substances 0.000 claims abstract description 11
- 239000003899 bactericide agent Substances 0.000 claims abstract description 11
- 239000003906 humectant Substances 0.000 claims abstract description 10
- 239000010231 banlangen Substances 0.000 claims abstract description 5
- 241000628997 Flos Species 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 244000269722 Thea sinensis Species 0.000 claims description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 9
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 9
- 235000011477 liquorice Nutrition 0.000 claims description 9
- 241000205585 Aquilegia canadensis Species 0.000 claims description 8
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 8
- 235000008397 ginger Nutrition 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 6
- 244000141009 Hypericum perforatum Species 0.000 claims description 6
- 241000334160 Isatis Species 0.000 claims description 6
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 6
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 6
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 4
- 239000006172 buffering agent Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical group C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims description 4
- 229940005608 hypericin Drugs 0.000 claims description 4
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims description 4
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims description 4
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 3
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 229960005233 cineole Drugs 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 3
- 235000019477 peppermint oil Nutrition 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 244000273928 Zingiber officinale Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 17
- 210000000214 mouth Anatomy 0.000 abstract description 14
- 241000700605 Viruses Species 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 4
- 239000010839 body fluid Substances 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 4
- 230000009545 invasion Effects 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 241001122767 Theaceae Species 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- 201000007100 Pharyngitis Diseases 0.000 description 6
- 241000234314 Zingiber Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 229940095518 mouthwash product Drugs 0.000 description 4
- 230000003239 periodontal effect Effects 0.000 description 4
- 201000001245 periodontitis Diseases 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 3
- 206010009152 Chronic tonsillitis Diseases 0.000 description 3
- 208000032139 Halitosis Diseases 0.000 description 3
- 201000008197 Laryngitis Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229960004099 azithromycin Drugs 0.000 description 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 3
- 239000006189 buccal tablet Substances 0.000 description 3
- 201000009243 chronic laryngitis Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010044008 tonsillitis Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000009916 yin-huang Substances 0.000 description 3
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000034619 Gingival inflammation Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 208000001277 chronic periodontitis Diseases 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 201000005311 drug allergy Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010794 food waste Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000020333 oolong tea Nutrition 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical group COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- ZGDVRBVTNMQMEX-LDHZKLTISA-N (8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylhept-6-en-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)=C)C)[C@@]1(C)CC2 ZGDVRBVTNMQMEX-LDHZKLTISA-N 0.000 description 1
- PHZOWSSBXJXFOR-UHFFFAOYSA-N 2-Propenyl glucosinolate Natural products OCC1OC(SC(CC=C)=NOS(O)(=O)=O)C(O)C(O)C1O PHZOWSSBXJXFOR-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- PHZOWSSBXJXFOR-MYMDCHNCSA-N Sinigrin Natural products S(=O)(=O)(O/N=C(\S[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)/CC=C)O PHZOWSSBXJXFOR-MYMDCHNCSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MGRRGKWPEVFJSH-UHFFFAOYSA-N dianthrone Natural products C12=CC=CC=C2C(=O)C2=CC=CC=C2C1=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MGRRGKWPEVFJSH-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- QKFAFSGJTMHRRY-OCFLFPRFSA-M potassium;[(e)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate Chemical compound [K+].OC[C@H]1O[C@@H](S\C(CC=C)=N\OS([O-])(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O QKFAFSGJTMHRRY-OCFLFPRFSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000017291 sinigrin Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000005092 sublimation method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种中药漱口水,属于日用品领域。本发明所述中药漱口水包括以下重量份的组分:保湿剂15~30份、清新剂0.2~0.7份、中药提取物15~30份、杀菌剂0.03~0.05份以及抗病毒剂0.01~0.02份;所述中药提取物的原料包括甘草、金银花、贯叶连翘、姜、板蓝根、薄荷以及单枞茶叶。该中药漱口水相比于传统漱口水,其含有的中药提取物与杀菌剂、抗病毒剂以及清新剂等相互搭配,协同增效,具有有益的选择性灭菌效果,维护口腔的微生态平衡;所述产品同时具有抗病毒、抗炎和生津的作用,充分保护人体免受有害微生物入侵的同时,给予使用者更好的漱口水使用体验。本发明还公开了所述中药漱口水的制备方法,该制备方法操作步骤简单,可实现工业化大规模生产。
Description
技术领域
本发明涉及日用品领域,具体涉及一种中药漱口水。
背景技术
市场上常见的漱口水目前单独用于口腔内含漱,其主要作用是祛除口臭和预防龋齿。然而现有漱口水配方普遍具有强大杀菌效力,长期使用有造成口腔微生态失调的可能。中药漱口水一般是在漱口水配方中加入中药提取物,经搅拌混合,陈化和过滤后,产生成品。常用的中药提取方式有溶剂提取法,水蒸气蒸熘法,升华法,所得产物再经分离和纯化。中药漱口水中的中药提取物通常是粉末或浸膏,失去原有中药材天然芬芳气味和口感,通常带有苦,涩,酸等不良气味和口感,不易为人群接受和坚持使用。
此外,现有漱口水配方对病毒作用效果不显著,而几乎所有呼吸道病毒和消化道病毒,都是经口咽腔进入,吸附于口咽腔黏膜,突破口咽环淋巴防御系统(包括扁桃体,腺样体,咽后壁淋巴滤泡,舌轮廓乳头,叶状乳头),感染人体;现有漱口水仅用于口腔,有起泡和清除食物碎屑的作用,并能短暂祛除口臭和预防龋齿,但不能生津,即刺激自身唾液分泌,并在用于咽喉部自体冲洗和消毒时,体验不佳。
发明内容
基于现有技术的不足,本发明的目的在于提供了一种中药漱口水,该产品保持选择性抗菌能力,同时具有良好的抗病毒能力,能调节口腔微生态平衡,使用时也具有较好体验。
为了达到上述目的,本发明采取的技术方案为:
一种中药漱口水,包括以下重量份的组分:保湿剂15~30份、清新剂0.2~0.7份、中药提取物15~30份、杀菌剂0.03~0.05份以及抗病毒剂0.01~0.02份;所述中药提取物的原料包括甘草、金银花、贯叶连翘、姜、板蓝根、薄荷以及单枞茶叶。
本发明所述中药提取物的原料中,甘草的化学组成极为复杂,从中提纯分离得到的化合物包括甘草甜素,甘草次酸,甘草甙等数十种成分,其功能主治清热解毒,祛痰止咳,生津解热等;贯叶连翘中可提取分离提取出金丝桃素,具有极强的抗病毒作用,具有疏肝解郁,清热利湿,消肿止痛的功能;金银花又名忍冬,其化学组成极为复杂,提取后的主要成分有木樨草素,绿原酸等,均具有较强的抗菌消炎作用;姜含有辛辣和芳香成分,辛辣成分为姜油酮,具有一定镇痛解热及消炎作用;板蓝根为十字花科植物菘蓝的干燥根,含有靛蓝,黑芥子甙及多种氨基酸等有效成分,具有清热解毒,凉血,利咽的功效;薄荷是一种芳香植物,其主要成分为薄荷醇,薄荷酮,乙酸薄荷酯等,可用于治疗流行性感冒,头疼,目赤身热,咽喉牙床肿痛等症状;单枞茶叶中含有有机化学成分达450多种,无机矿物元素40多种,其有效成分主要有茶多酚,累胆甾烯,咖啡碱等,其主要功能有抗氧化,预防龋齿,消除口臭等。
本发明所提供的中药漱口水产品,相比于传统漱口水,其含有的中药提取物与杀菌剂、抗病毒剂以及清新剂等相互搭配,协同增效,具有有益的选择性灭菌效果,维护口腔的微生态平衡;所述产品同时具有抗病毒、抗炎和生津的作用,充分保护人体免受有害微生物入侵的同时,给予使用者更好的漱口水使用体验。
优选地,所述中药提取物的制备方法包括以下步骤:
(1)将甘草、金银花、贯叶连翘、姜、板蓝根、薄荷以及单枞茶叶在质量浓度为40~50%的乙醇水溶液中浸渍40~50h,得混合物A;
(2)将步骤(1)所得混合物A超声提取1~3h后,静置40~50h,过滤,得固体过滤物B和滤液C;
(3)将步骤(2)所得固体过滤物B加水并加热提取2~4次后过滤,所得滤液与步骤(2)所得滤液C混合,静置后过滤杂质,即得所述中药提取物。
所述中药提取物的制备方法将原料依次乙醇提取和水相提取,所得产品中有效功能组分更加丰富,提取程度更加完全,含量更高;产品无需后续分离和纯化,可直接与配方组分混合,增大了中药组分在漱口水产品中的有效浓度,减少了化学药剂的残留;同时所述制备步骤操作简单,对制备设备要求低。
优选地,所述步骤(1)所述甘草、金银花、贯叶连翘、姜、板蓝根、薄荷以及单枞茶叶的质量比为2:1:1:1:1:1:1。
优选地,所述保湿剂包括以下重量份的组分:山梨醇7~15份和丙三醇8~15份。
所述特定含量的保湿剂作为基体溶剂可有效保证各组分充分混合的同时,可在产品在使用时对接触的人体口腔组织进行保湿润滑。
优选地,所述清新剂包括以下重量份的组分:薄荷油0.1~0.5份和桉叶油素0.1~0.2份。
所述薄荷油和桉叶油素均具有特殊的清凉香气和辛凉口感,按特定比例搭配后可使制备的中药漱口水产品具有良好的使用口感,使用后保留清新的口气。
优选地,所述杀菌剂为月桂醇硫酸酯钠。
月桂醇硫酸酯钠对部分微生物具有微毒性,通过适量的搭配使用可在有效抵御有害细菌的同时,维持口腔的微生态平衡。
优选地,所述抗病毒剂为金丝桃素。
金丝桃素属于二蒽酮类化合物,具有极强的抗病毒作用,同时按特定比例下使用也可有效提高免疫力。
优选地,所述中药漱口水的组分还包括增溶剂、缓冲剂、防腐剂、赋香剂、稀释剂中的至少一种。
优选地,所述增溶剂为氢化蓖麻油;所述缓冲剂为柠檬酸钠;所述防腐剂为羟苯甲酯;所述赋香剂为香精;所述稀释剂为去离子水。
本发明的另一目的还在于提供所述中药漱口水的制备方法,包括以下步骤:
(1)将保湿剂和中药提取物混合搅拌均匀,得混合物a;
(2)将稀释剂、杀菌剂、抗病毒剂、增溶剂、清新剂、缓冲剂和防腐剂混合搅拌均匀,得混合物b;
(3)在混合物b中加入混合物a并搅拌均匀,加入赋香剂继续混合均匀,陈化6~8日,待冷却至4~6℃并过滤后,即得所述中药漱口水。
本发明所述中药漱口水的制备方法操作步骤简单,可实现工业化大规模生产。
优选地,本发明还提供了所述中药漱口水的使用方法,所述使用方法为发明人为配合产品所发明的改良含漱方式,包括以下步骤:
(1)含小半口中药漱口水在口内,头尽量后仰,发长“啊”音,这时气道开口打开,水后流至口咽腔交界位置,在肺内呼出气流的带动下,反复冲洗黏膜和淋巴组织表面,清理表面粘液和附着的细菌和病毒等。
(2)停止发音,头回复正中位,中药漱口水流回口腔,鼓漱,在唇肌的带动下,水在牙齿间荡洗,清洁食物残渣等。
(3)上述过程重复2~3次,然后吐弃,重富上述1~4步,直至用完一杯中药漱口水。
所述方法可以通过往复运动锻炼颈椎;通过发声运动锻炼膈肌等深层呼吸肌肉,锻炼呼吸能力;通过鼓漱锻炼嘴巴附近肌肉,同时可有效清洁将口腔、咽腔甚至鼻腔等部分,从而促进预防上呼吸道感染、牙周病、慢性扁桃体炎等多种细菌病毒引起的疾病。
本发明的有益效果在于:本发明提供了一种中药漱口水,该产品相比于传统漱口水,其含有的中药提取物与杀菌剂、抗病毒剂以及清新剂等相互搭配,协同增效,具有有益的选择性灭菌效果,维护口腔的微生态平衡;所述产品同时具有抗病毒、抗炎和生津的作用,充分保护人体免受有害微生物入侵的同时,给予使用者更好的漱口水使用体验。本发明还提供了所述中药漱口水的制备方法,该制备方法操作步骤简单,可实现工业化大规模生产。
具体实施方式
若无特别说明,本发明实施例和对比例中所用原料均购自市场。
为了更好地说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明,其目的在于详细地理解本发明的内容,而不是对本发明的限制。
实施例1~4
本发明所述一种中药漱口水的实施例。
本实施例所述的中药漱口水配方如表1所示。
所述实施例中中药提取物的制备方法均相同,包括以下步骤:
(1)将甘草、金银花、贯叶连翘、姜、板蓝根、薄荷以及单枞茶叶在质量浓度为45%的乙醇水溶液中浸渍48h,得混合物A;所述甘草、金银花、贯叶连翘、姜、板蓝根、薄荷以及单枞茶叶的质量比为2:1:1:1:1:1:1。
(2)将步骤(1)所得混合物A超声提取2h后,静置48h,过滤,得固体过滤物B和滤液C;
(3)将步骤(2)所得固体过滤物B加水煮沸并加热提取3次后过滤,所得滤液与步骤(2)所得滤液C混合,静置2h后过滤杂质,即得所述中药提取物。
所述实施例中中药漱口水的制备方法均相同,包括以下步骤:
(1)将保湿剂和中药提取物混合搅拌均匀,得混合物a;
(2)将稀释剂、杀菌剂、抗病毒剂、增溶剂、清新剂、缓冲剂和防腐剂混合搅拌均匀,得混合物b;
(3)在混合物b中加入混合物a并搅拌均匀,加入赋香剂继续混合均匀,陈化7日,待冷却至5℃并过滤后,即得所述中药漱口水。
表1
对比例1~4
对比例1~3与实施例1的差别仅在于配方上的不同,对比例4与对比例1的差别仅在于,所述中药提取物的制备原料不含金银花和板蓝根,所述甘草、贯叶连翘、姜、薄荷以及单枞茶叶的质量比为2:1:1:1:1。
效果例1
为验证本发明所述中药漱口水的使用效果,将实施例1所得产品进行牙周炎治疗临床试验,同时使用西帕伊固龈液(新疆奇康哈博维药股份有限公司,国药准字Z65020012)作为对照试用品。牙周病是感染性疾病,对口腔卫生管理不佳,牙龈易红肿发炎出血的人群,需使用洗必泰进行口腔含漱,一天2次,一共14天。近年作为一种中草药漱口水,西帕依固龈液的研究应用较多,疗效得到肯定。本研究选取西帕依固龈液作为对比,具有可信度。
受试对象:选取2020年3月~2020年6月确诊64名慢性牙周炎患者作为研究对象。年龄16~67岁,平均47.8岁。两组一般资料比较差异无统计学意义(P>0.05),具有可比性。
所述研究对象的纳入标准:①无全身系统性疾病;②否认药物过敏史;③牙周基线检查BPE>1;④3个月内未使用过任何抗菌药物和漱口水;⑤依从性良好。
研究对象的排除标准:①近3个月内使用过抗生素;②过敏性体质或有全身系统性疾病。③缺失牙数>2个
检验标准
选取6颗指数牙:11,16,26,31,36,46;检查每一颗指数牙的BI(出血指数)。
BI检查方法:将标准牙周探针探入龈沟或袋底,轻轻加力(20g施加压力)接触龈沟内上皮,探完等待30s,记录各点位有无出血及出血程度。其中出血程度以:0=牙龈健康,无炎症及出血;1=牙龈颜色有炎症性改变,探诊不出血;2=探诊后有点状出血;3=探诊出血沿龈缘扩散,4=出血流满并溢出龈沟;5=自动出血来进行表示。将受试者6颗指数牙的每一BI指数相加,再除以6,即得到该受试者的BI数值。BI(出血指数)是一种比较准确且客观地判断牙龈炎症的指数记分法。它比较精细,更为客观,适用于牙龈炎症较重的人群观察治疗前后效果的临床研究。
实验方法和步骤
将实施例1所得产品和对照试验用品两种漱口水由实验编组人员统一装瓶,贴号,记录,分发。患者被随机分为2组,分别分发漱口水。每一患者由护士教导正确的使用方法。患者归家后按照方法,早晚两次,连续使用14天。期间如有不适停止使用,并报告备案。14天后将漱口水样品带回,再次检查BI。所有牙周检查由同一名医师进行。最后由实验编组人员将实验结果还原为实施例1对应的研究组(A组)和对照试验用品对应的对照组(B组)。
统计学方法
应用SPSS20.0统计学软件对数据进行分析,计量资料采用t检验,以P<0.05为差异有统计学意义。
实验过程中2名患者因个人原因退出本实验,A组0名,B组2名,失访率为3%,满足实验设计要求。其余志愿者依从性良好,所有志愿者未出现明显不良反应。使用漱口水前A,B两组的BI差异无统计学意义(P>0.05),牙龈均有不同程度的质地松软,红肿光亮。使用漱口水14天后,牙龈颜色变浅,肿胀程度减轻,出血位点减少。A,B两组的BI较使用前均有不同程度降低,差异有统计学意义(P<0.05);A、B两组间BI差异均无统计学意义(P>0.05)。BI的结果见表1。
表1
分组 | 人数 | 使用前 | 使用后 | t | P |
A | 32 | 3.920±0.137 | 1.185±0.116 | 9.501 | <0.001 |
B | 30 | 3.781±0.192 | 1.257±0.122 | 8.729 | <0.001 |
t | 0.005 | 1.105 | |||
P | 0.970 | 0.683 |
本实验结果显示,在两组患者中,出血指数在使用前后差异均具有统计学意义(P<0.05),其牙周健康改善明显,牙龈红肿程度有所降低,牙龈出血程度减轻明显,说明本发明所提供的中药漱口水产品具有良好的牙龈炎症治疗效果。
效果例2
为验证本发明所述中药漱口水的使用效果,将实施例1、对比例1~4所得产品进行咽喉治疗临床试验,同时使用对照组用阿奇霉素和银黄含化片作为对照试用品。慢性咽炎为咽部黏膜,黏膜下及淋巴组织的弥漫性慢性炎症。慢性喉炎是指喉部慢性非特异性炎症。慢性咽炎,慢性喉炎,慢性扁桃体炎,牙周炎之间互相影响,病毒细菌与炎性分泌物反复刺激咽喉部淋巴防御环,造成疾病反复发作或迁延不愈,因此任何将他们分隔独立治疗的方法,其疗效效果有限。长期应用抗生素容易出现耐药,人体菌群失调,免疫力下降等不良反应。
受试对象:2019年3月~2020年1月确诊的246名咽喉炎患者作为研究对象,随机分为两组。年龄26~73岁,平均48.51±5.12岁。两组一般资料比较差异无统计学意义(P>0.05),具有可比性。
所述研究对象的纳入标准:①无全身系统性疾病;②否认药物过敏史;③符合急慢性咽喉炎相关诊断标准;④3个月内未使用过任何抗菌药物和漱口水;⑤依从性良好。
所述研究对象的排除标准:①近3个月内使用过抗生素;②过敏性体质或有全身系统性疾病。③存在精神疾病或认知障碍
观察指标
咽喉部水肿充血,淋巴滤泡等临床症状,体征消失为显效;临床症状,体征明显好转,趋向消失为有效。临床症状,体征无明显改善为无效。
根据《中药新药临床研究指导原则》中慢性咽喉炎相关标准,将临床症状改善程度分为无症状,轻度症状,中度症状,重度症状4个等级。评分为0~4分,评分内容包括声音嘶哑、咽喉干燥、喉内异物感、咳痰不爽和咽喉痛五个症状。
实验步骤和方法
将对照组的患者使用阿奇霉素和银黄含化片,其中阿奇霉素每日口服一次,每次0.5g,银黄含化片每日口服含化使用三次,每次1片。实验组使用实施例1所得中草药漱口水,一日2~3次,每次合并鼓漱3分钟。两组7天为一个疗程,治疗3个疗程。对比组使用对比例1~4所得中草药漱口水,一日2~3次,每次合并鼓漱3分钟。两组7天为一个疗程,治疗3个疗程。疗程过后由实验编组人员将实验结果统计为实施例1对应的研究组和对照试验用品对应的对照组。
统计学方法
应用SPSS20.0统计学软件对数据进行分析,计量资料采用t检验,以P<0.05为差异有统计学意义。计数资料采用卡方检验,以P<0.05为差异有统计学意义。
测试结果如表2和表3所示。
表2
表3
从表2和表3可以看出,本发明所得的中药漱口水对慢性咽喉炎具有良好的治疗效果,有效人数均高于对照组和对比组,而总体的疗效甚至好于使用药物治疗的对照组,说明本发明所得中药漱口水具有优异的抗病毒、抗菌和消炎效果。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (10)
1.一种中药漱口水,其特征在于,包括以下重量份的组分:保湿剂15~30份、清新剂0.2~0.7份、中药提取物15~30份、杀菌剂0.03~0.05份以及抗病毒剂0.01~0.02份;所述中药提取物的原料包括甘草、金银花、贯叶连翘、姜、板蓝根、薄荷以及单枞茶叶。
2.如权利要求1所述的中药漱口水,其特征在于,所述中药提取物的制备方法包括以下步骤:
(1)将甘草、金银花、贯叶连翘、姜、板蓝根、薄荷以及单枞茶叶在质量浓度为40~50%的乙醇水溶液中浸渍40~50h,得混合物A;
(2)将步骤(1)所得混合物A超声提取1~3h后,静置40~50h,过滤,得固体过滤物B和滤液C;
(3)将步骤(2)所得固体过滤物B加水并加热提取2~4次后过滤,所得滤液与步骤(2)所得滤液C混合,静置后过滤杂质,即得所述中药提取物。
3.如权利要求2所述的中药漱口水,其特征在于,所述步骤(1)所述甘草、金银花、贯叶连翘、姜、板蓝根、薄荷以及单枞茶叶的质量比为2:1:1:1:1:1:1。
4.如权利要求1所述的中药漱口水,其特征在于,所述保湿剂包括以下重量份的组分:山梨醇7~15份和丙三醇8~15份。
5.如权利要求1所述的中药漱口水,其特征在于,所述清新剂包括以下重量份的组分:薄荷油0.1~0.5份和桉叶油素0.1~0.2份。
6.如权利要求1所述的中药漱口水,其特征在于,所述杀菌剂为月桂醇硫酸酯钠。
7.如权利要求1所述的中药漱口水,其特征在于,所述抗病毒剂为金丝桃素。
8.如权利要求1所述的中药漱口水,其特征在于,所述中药漱口水的组分还包括增溶剂、缓冲剂、防腐剂、赋香剂、稀释剂中的至少一种。
9.如权利要求8所述的中药漱口水,其特征在于,所述增溶剂为氢化蓖麻油;所述缓冲剂为柠檬酸钠;所述防腐剂为羟苯甲酯;所述赋香剂为香精;所述稀释剂为去离子水。
10.如权利要求1~9任一项所述中药漱口水的制备方法,其特征在于,包括以下步骤:
(1)将保湿剂和中药提取物混合搅拌均匀,得混合物a;
(2)将稀释剂、杀菌剂、抗病毒剂、增溶剂、清新剂、缓冲剂和防腐剂混合搅拌均匀,得混合物b;
(3)在混合物b中加入混合物a并搅拌均匀,加入赋香剂继续混合均匀,陈化6~8日,待冷却至4~6℃并过滤后,即得所述中药漱口水。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011392554.2A CN112336663A (zh) | 2020-12-02 | 2020-12-02 | 一种中药漱口水 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011392554.2A CN112336663A (zh) | 2020-12-02 | 2020-12-02 | 一种中药漱口水 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112336663A true CN112336663A (zh) | 2021-02-09 |
Family
ID=74427488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011392554.2A Pending CN112336663A (zh) | 2020-12-02 | 2020-12-02 | 一种中药漱口水 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112336663A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113350239A (zh) * | 2021-06-25 | 2021-09-07 | 山西工商学院 | 一种老陈醋多功能漱口水及其制备方法 |
CN113476386A (zh) * | 2021-08-19 | 2021-10-08 | 杭州迅腾医疗器械有限公司 | 一种漱口液及其制备方法 |
CN114392212A (zh) * | 2021-12-10 | 2022-04-26 | 江苏德和生物科技有限公司 | 一种茶黄素组合物、制备方法及应用 |
EP4094756A1 (en) * | 2021-05-26 | 2022-11-30 | Hirsch-Apotheke, Wolfgang Scholz e.K. | Compositions for treating sars-cov2 infection |
WO2022248564A1 (en) * | 2021-05-26 | 2022-12-01 | Hirsch-Apotheke, Wolfgang Scholz E.K. | Compositions for treating sars-cov2 infection |
CN116173110A (zh) * | 2022-12-30 | 2023-05-30 | 深圳市宝安纯中医治疗医院 | 一种中药抗病毒漱口水的制备与应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996016633A1 (en) * | 1994-12-02 | 1996-06-06 | Warner-Lambert Company | Reduced alcohol mouthwash |
US20060045860A1 (en) * | 2004-08-26 | 2006-03-02 | Bioderm Research | Zinc Zeolite Based Deodorants and Deodorizers |
CN102727408A (zh) * | 2012-06-14 | 2012-10-17 | 董家华 | 一种生物环保抗病毒防感冒牙膏及其制备方法 |
CN106619284A (zh) * | 2016-12-08 | 2017-05-10 | 西安中天生物医药有限公司 | 一种用于口腔抑菌和口气清新的重要漱口水及其配制方法 |
CN108721180A (zh) * | 2018-06-29 | 2018-11-02 | 重庆登康口腔护理用品股份有限公司 | 一种含金银花的抑菌口腔组合物、制品及其制备方法 |
US20180360735A1 (en) * | 2016-12-21 | 2018-12-20 | Mge Holdings Llc | Oral Care Products and Methods |
CN109549887A (zh) * | 2017-09-27 | 2019-04-02 | 舒维 | 一种消炎漱口水 |
CN109549886A (zh) * | 2017-09-27 | 2019-04-02 | 舒维 | 一种消炎漱口水的制备方法 |
CN110731989A (zh) * | 2018-07-18 | 2020-01-31 | 九芝堂股份有限公司 | 一种口喷产品及其制备方法和应用 |
-
2020
- 2020-12-02 CN CN202011392554.2A patent/CN112336663A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996016633A1 (en) * | 1994-12-02 | 1996-06-06 | Warner-Lambert Company | Reduced alcohol mouthwash |
US20060045860A1 (en) * | 2004-08-26 | 2006-03-02 | Bioderm Research | Zinc Zeolite Based Deodorants and Deodorizers |
CN102727408A (zh) * | 2012-06-14 | 2012-10-17 | 董家华 | 一种生物环保抗病毒防感冒牙膏及其制备方法 |
CN106619284A (zh) * | 2016-12-08 | 2017-05-10 | 西安中天生物医药有限公司 | 一种用于口腔抑菌和口气清新的重要漱口水及其配制方法 |
US20180360735A1 (en) * | 2016-12-21 | 2018-12-20 | Mge Holdings Llc | Oral Care Products and Methods |
CN109549887A (zh) * | 2017-09-27 | 2019-04-02 | 舒维 | 一种消炎漱口水 |
CN109549886A (zh) * | 2017-09-27 | 2019-04-02 | 舒维 | 一种消炎漱口水的制备方法 |
CN108721180A (zh) * | 2018-06-29 | 2018-11-02 | 重庆登康口腔护理用品股份有限公司 | 一种含金银花的抑菌口腔组合物、制品及其制备方法 |
CN110731989A (zh) * | 2018-07-18 | 2020-01-31 | 九芝堂股份有限公司 | 一种口喷产品及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
王建新: "<<化妆品植物原料大全>>", 30 June 2012 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4094756A1 (en) * | 2021-05-26 | 2022-11-30 | Hirsch-Apotheke, Wolfgang Scholz e.K. | Compositions for treating sars-cov2 infection |
EP4094755A1 (en) * | 2021-05-26 | 2022-11-30 | Hirsch-Apotheke, Wolfgang Scholz e.K. | Compositions for treating sars-cov2 infection |
WO2022248564A1 (en) * | 2021-05-26 | 2022-12-01 | Hirsch-Apotheke, Wolfgang Scholz E.K. | Compositions for treating sars-cov2 infection |
CN113350239A (zh) * | 2021-06-25 | 2021-09-07 | 山西工商学院 | 一种老陈醋多功能漱口水及其制备方法 |
CN113476386A (zh) * | 2021-08-19 | 2021-10-08 | 杭州迅腾医疗器械有限公司 | 一种漱口液及其制备方法 |
CN114392212A (zh) * | 2021-12-10 | 2022-04-26 | 江苏德和生物科技有限公司 | 一种茶黄素组合物、制备方法及应用 |
CN116173110A (zh) * | 2022-12-30 | 2023-05-30 | 深圳市宝安纯中医治疗医院 | 一种中药抗病毒漱口水的制备与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112336663A (zh) | 一种中药漱口水 | |
CN108785161B (zh) | 一种含甘草黄酮的抑菌漱口水及其制备方法 | |
CN106924106B (zh) | 一种用于抑制牙菌斑和减轻牙龈炎症的牙膏 | |
US20120288454A1 (en) | Dental protection toothpaste composition | |
CN110812316A (zh) | 一种含有多种中药组合物的牙膏和制备方法及其应用 | |
CN105310960A (zh) | 一种新型多糖抗菌漱口液及其制备方法 | |
CN108815232A (zh) | 一种草本抗菌液 | |
CN115068383A (zh) | 一种漱口水及其制备方法 | |
WO2016010284A1 (ko) | 울금을 함유한 치약 조성물 및 그 제조 방법 | |
CN101007088A (zh) | 一种治疗牙周疾病的中药组合物及其制备方法 | |
CN109157574B (zh) | 一种用于危重患者口腔护理的中药组合物及含其口腔护理液 | |
WO2006059196A1 (en) | Compositions for the acute and/or long term treatment of periodontal diseases | |
CN104814907A (zh) | 治疗牙龈出血的牙膏 | |
CN113520957A (zh) | 一种针对牙龈炎牙龈萎缩的中草药牙膏配方及其制备方法 | |
CN106974866A (zh) | 一种艾叶配方牙膏及其制备方法 | |
CN108743497A (zh) | 一种植物源抑菌漱口水及其制备方法 | |
CN113520962A (zh) | 一种用于口腔生态护理的组合物及其制备方法和应用 | |
CN112137928A (zh) | 一种多重功效牙膏及其制备方法 | |
CN113230335A (zh) | 一种治疗牙龈肿痛的中药漱口水及其制备工艺 | |
CN112717030B (zh) | 一种防治口腔疾病的药物组合物及其制备方法和用途 | |
CN110638891A (zh) | 一种止咳口服液 | |
CN109646591B (zh) | 一种用于口腔的组合物及其应用 | |
Mahant et al. | Home remedies for dental diseases in the Pandemic of COVID-19-A Systematic Review | |
CN114699481B (zh) | 一种治疗咽喉肿痛的中药及其制备方法 | |
CN107519377B (zh) | 一种抑菌消炎组合物及其制备方法和口腔保健护理产品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210209 |